LBL-007 is under clinical development by BeiGene and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how LBL-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
LBL-007 is under development for the treatment of advanced solid tumors, advanced lymphomas, biliary tract cancer, metastatic colorectal cancer and metastatic melanoma. The drug candidate acts by targeting lymphocyte activation gene 3 protein (LAG3). It is administered through intrapulmonary and intravenous routes.
BeiGene is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. The company offers BRUKINSA, a BTK (Bruton’s tyrosine kinase) inhibitor against mantle cell lymphoma (MCL). BeiGene is investigating Zanubrutinib (BGB-3111), a small molecule inhibitor of BTK to treat B cell malignancies; Tislelizumab (BGB-A317), a monoclonal antibody targeting solid tumors and hematologic cancer; and Pamiparib (BGB-290) against solid tumor malignancies. It seeks to work in partnership with academia, biotechnology and pharmaceutical companies to develop treatments for cancer patients. The company has operations in the US, Australia, Germany, Spain Switzerland, and Italy. BeiGene is headquartered in Beijing, China.
For a complete picture of LBL-007’s drug-specific PTSR and LoA scores, buy the report here.